Dr. Wells is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
124 Sunset Ct
West Columbia, SC 29169Phone+1 803-931-0077Fax+1 803-931-0076
Education & Training
- Emory University School of MedicineResidency, Ophthalmology, 1988 - 1991
- Emory University School of MedicineResidency, Internal Medicine, 1986 - 1988
- Emory University School of MedicineClass of 1986
- Washington and Lee UniversityBS, Biology, Magna Cum Laude, 1978 - 1982
Certifications & Licensure
- SC State Medical License 1991 - 2025
- TN State Medical License 2024 - 2025
- GA State Medical License 1988 - 2005
- American Board of Ophthalmology Ophthalmology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification NextGen Ambulatory EHR, NextGen Healthcare, 2012
- President Medical Journal Club, 2001
- Vice-President Medical Journal Club, 2000
- Join now to see all
Publications & Presentations
PubMed
- 630 citationsAflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.John A. Wells, Adam R. Glassman, Allison R. Ayala, Lee M. Jampol, Neil M. Bressler
Ophthalmology. 2016-06-01 - 16 citationsFaricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.Tien Y Wong, Zdenka Haskova, Kemal Asik, Caroline R Baumal, Karl G Csaky
Ophthalmology. 2024-06-01 - 35 citationsAnti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.Lee M. Jampol, Adam R. Glassman, Neil M. Bressler, John A. Wells, Allison R Ayala
JAMA Ophthalmology. 2016-12-01
Journal Articles
- Factors Associated With Changes in Visual Acuity and Central Subfield Thickness at 1 Year After Treatment for Diabetic Macular Edema With RanibizumabSusan B. Bressler, MD; Haijing Qin, MS; Roy W. Beck, MD, PhD; Kakarla V. Chalam, MD; Judy E. Kim, MD; Michele Melia, ScM; John A. Wells III, MD; for the Diabetic Retin..., Arch Ophthalmol, 1/1/2012
- Expanded 2-year Follow-up of a Trial Evaluating Ranibizumab Plus Prompt or Deferred Laser or Triamcinolone Plus Prompt Laser for Diabetic Macular EdemaThe Diabetic Retinopathy Clinical Research Network, Ophthalmology, 4/1/2011
- Ranibizumab and Bevacizuamb for Neovascular Age-related Macular DegenerationThe CATT Research Group, N Engl J Med, 1/1/2011
- Join now to see all
Abstracts/Posters
- Factors Associated with Changes in Visual Acuity and OCT Thickness at One Year after Treatment with Ranibizumab for DMEWells JA for the Diabetic Retinopathy Clinical Research Network, 29th Annual Meeting of the American Society of Retina Specialists, Boston, MA, 8/22/2011
- Failure of Intravitreal Bevacizumab Therapy for Neovascular AMD Followed by Successful Response to Intravitreal RanibizumabKatz B and Wells JA, ARVO Annual Meeting, Fort Lauderdale, FL, 5/1/2011
- Pegaptanib Sodium (Macugen) In the Treatment of Diabetic Macular Edema (DME): A Case Series from Two Clinical PracticesWells JA, Driver MC, Retina Congress 2009 New York: A Combined Meeting of the American Society of Retina Specialists, The Retina Society and the Macula Society, New York, NY, 10/1/2009
- Join now to see all
Lectures
- Ranibizumab and Bevicizumab for Neovascular AMD. Age-Related Macular Degeneration: Fundamental Aspects and Translation into New TreatmentsBaden-Baden, Germany - 9/8/2011
- Number of Laser-ranibizumab-triamcinolone Treatments for Diabetic Macular EdemaKyoto, Japan - 11/6/2010
- DRCR Network Panel Discussion on Diabetic Macular EdemaChicago, IL - 10/16/2010
- Join now to see all
Professional Memberships
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: